UNIQUE

📅 Upcoming

🕒 Recent(90d)

News

• Convenience Kit Correction: Argon Medical Issues Correction for Convenience Kits Containing Spectra Medical Device Lidocaine Ampules
  Argon Medical is correcting affected convenience kits by removing included Spectra Medical Devices Lidocaine Ampules.
  fda_medwatch · 1d ago
• ‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence
  A standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.
  fiercebiotech · 1d ago
• GSK cost-cutting plan includes global layoffs
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• Opinion: The VA could help America win the biotechnology race with China
  “Together, HHS, the VA, and the DOD form a strong American innovation ecosystem — one that China and other competitors cannot easily replicate,” writes former VA Secretary David Shulkin.
  stat · 1d ago
• The FDA was all in on AI. Will that change?
  High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
  biopharma_dive · 2d ago
• As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
  When signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.
  biospace · 2d ago
• Opinion: How midwives like me can help fight medical misinformation
  “I have come to believe that changing a mind is rarely the point. Planting a seed is,” writes nurse-midwife Mara Evans.
  stat · 3d ago
• Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
  Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
  fiercebiotech · 3d ago
• There are already more U.S. measles cases this year than in all of 2025
  The number of measles cases in the U.S. has surpassed the record-breaking tally for all of 2025, with five more months of 2026 still to come.
  stat · 6d ago
• Amgen deploys patients to defend troubled Tavneos in FDA hearing request
  Facing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.
  biospace · 6d ago